TCRX — Tscan Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $90.55m
- -$167.49m
- $2.82m
Annual cashflow statement for Tscan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.1 | -48.6 | -66.2 | -89.2 | -127 |
| Depreciation | |||||
| Non-Cash Items | 0.517 | 2.52 | 4.81 | 4.89 | 7.51 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 21.4 | -5.9 | -10.2 | 17.6 | 5.05 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -3.02 | -48.7 | -66.5 | -61.4 | -111 |
| Capital Expenditures | -4.24 | -9.94 | -4.22 | -3.15 | -3.83 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -57.6 | -48.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -4.24 | -9.94 | -4.22 | -60.8 | -52.6 |
| Financing Cash Flow Items | — | — | -0.131 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.288 | 190 | 29.4 | 135 | 209 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -6.97 | 131 | -41.4 | 13.3 | 45.3 |